A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial

References

• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44. doi:10.1200/JCO.2003.11.136. PMID:12860938.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14. doi:10.1016/S0140-6736(15)01238-6. PMID:26719230.
   PubMed Web of Science ®Google Scholar
• Wong RM, Ianculescu I, Sharma S, Gage DL, Olevsky OM, Kotova S, Kostic MN, Grundfest WS, Hou D, Cameron RB. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects. Am J Respir Cell Mol Biol. 2014;50:870–5. doi:10.1165/rcmb.2013-0472TR. PMID:24450537.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer. 2001;32:197–201. doi:10.1016/S0169-5002(00)00217-8. PMID:11325491.
   PubMed Web of Science ®Google Scholar
• Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T, Torigoe T, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:1543–9. doi:10.1007/s00262-010-0881-6. PMID:20567822.
   PubMed Web of Science ®Google Scholar
• Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug LM, Adusumilli PS. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4:e1009285. doi:10.1080/2162402X.2015.1009285. PMID:26155428.
   PubMed Web of Science ®Google Scholar
• Ireland DJ, Kissick HT, Beilharz MW. The Role of Regulatory T Cells in Mesothelioma. Cancer Microenviron. 2012;5:165-72. doi:10.1007/s12307-012-0100-4. PMID:22302659.
   PubMedGoogle Scholar
• McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother. 2013;62:529-39. doi:10.1007/s00262-012-1360-z. PMID:23069871.
   PubMed Web of Science ®Google Scholar
• Cornwall SM, Wikstrom M, Musk AW, Alvarez J, Nowak AK, Nelson DJ. Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. Oncoimmunology. 2016;5:e1082028. doi:10.1080/2162402X.2015.1082028. PMID:27057464.
   PubMed Web of Science ®Google Scholar
• Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16:5805–13. doi:10.1158/1078-0432.CCR-10-2245. PMID:20956618.
   PubMed Web of Science ®Google Scholar
• Tanrikulu AC, Abakay A, Komek H, Abakay O. Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma. Environ Health Prev Med. 2016;21:304–11. doi:10.1007/s12199-016-0530-6. PMID:27068290.
   PubMed Web of Science ®Google Scholar
• Zhang A, Cao S, Jin S, Cao J, Shen J, Pan B, Zhu R, Yu Y. Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. Neoplasma. 2017;64:114–22. doi:10.4149/neo_2017_114. PMID:27881012.
   PubMed Web of Science ®Google Scholar
• Zauderer GM, Dao T, Rusch V, Ginsberg M, Tsao A, Panageas K, al. e. Randomized Phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodal therapy. J Clin Oncol. 2016;34: Abstract 8519.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02716272?term = mesothelioma+nivolumab&rank = 1.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02399371?term = mesothelioma+pembrolizumab&rank = 1.
   Google Scholar
• Hole N, Barton-Hanson N, Berwick S, Stern P. Human trophoblast glycoproteins defined by monoclonal antibody 1D2. Exp Cell Biol. 1988;56:39–48. PMID:3053282.
   PubMedGoogle Scholar
• Al-Taei S, Salimu J, Lester JF, Linnane S, Goonewardena M, Harrop R, Mason MD, Tabi Z. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer. 2012;77:312–8. doi:10.1016/j.lungcan.2012.03.008. PMID:22498111.
   PubMed Web of Science ®Google Scholar
• Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother. 2010;33:999–1005. doi:10.1097/CJI.0b013e3181f5dac7. PMID:20948436.
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008;57:977–86. doi:10.1007/s00262-007-0428-7. PMID:18060404.
   PubMed Web of Science ®Google Scholar
• Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60. doi:10.1093/annonc/mdh059. PMID:14760119.
   PubMed Web of Science ®Google Scholar
• Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 2005;65:7000–6. doi:10.1158/0008-5472.CAN-04-3792. PMID:16061686.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, et al. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2013;83:728–38. doi:10.1002/cyto.a.22319. PMID:23788464.
   PubMedGoogle Scholar
• Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman HL, de Belin J, Kelleher M, Goonewardena M, et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother. 2011;60:829–37. doi:10.1007/s00262-011-0993-7. PMID:21387109.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1504627. PMID:26028407.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627–39. doi:10.1056/NEJMoa1507643. PMID:26412456.
   PubMed Web of Science ®Google Scholar
• Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, Johnston MR, de Perrot M. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008;135:823–9. doi:10.1016/j.jtcvs.2007.10.026. PMID:18374762.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B, Tiseo M. Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. J Thorac Oncol. 2016;11:1819–36. doi:10.1016/j.jtho.2016.05.027. PMID:27288978.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Scherpereel A, Calabro L, Aerts JG, Cedres Perez S, Bearz A. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. J Clin Oncol. 2016;34: Abstract 8502.
   Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86. doi:10.1084/jem.20030152. PMID:14676299.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150. doi:10.1038/ncomms12150. PMID:27381735.
   PubMed Web of Science ®Google Scholar